spacer
home > pmps > autumn 2013 > sustainable savings
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Sustainable Savings

PMPS: Aside from the obvious environmental benefits, why should pharma companies push for a green supply chain?

Christoph Hammer: Ecological packaging ties in closely with cost savings. Large pharma companies put a huge emphasis on this – not only do they want to play a part in preserving the planet, they want to protect their own businesses as well. The environment and financial gain go hand in hand.

What are the main challenges of incorporating these factors into current systems?

There is a large base of already-installed old technology and equipment to contend with – old habits die hard, and companies can be slow to adapt or change to new solutions. But this is gradually changing – for example, the US National Environmental Policy Act and many environmental organisations push hard to avoid using plastic and PVC where possible.

World regions are following suit, and more initiatives are being introduced all the time. In the BRIC countries (Brazil, Russia, India and China), the importance of a green supply chain is becoming a major issue.

What is Total Cost of Packaging (TCP)?

Overall costs are closely linked to packaging and logistics. For the secondary packaging of parenteral products, for example, we keep the whole financial picture in mind: by using mono-material on the inbound (flat carton blanks), outbound (compact packs) and disposal processes, cost reduction is a given. Mono-materials are also made environmentally friendly very easily, by producing them in recyclable products such as paperboard.

TCP can also contribute to a greener supply chain by tackling hidden costs with regard to logistics, volume transportation, stocking and storage. We feel that TCP thinking leads to sustainable solutions.

What other benefits can TCP bring to pharma companies?


The following case study should help me answer this question. A well-known pharma company, wishing to reduce their expenses, approached us for advice. Using TCP methods, we looked at the full picture in order to solve the problem.

With this in mind, a 10-count syringe carton was designed to meet the growing demands of the company’s flu vaccine franchise, resulting in increased output, higher equipment efficiency, reduced package material costs and lower cold chain distribution costs.

The top-load carton was made from fully recyclable paperboard material and eliminated the need for pre-made plastic trays and lid material, resulting in savings in excess of $1,000,000 annually. A 50 per cent reduction in pack volume was able to cut expensive cold chain shipping and storage costs by half. The top-loading syringe cartoning system provided four times the throughput of the previous process, with a capacity of producing 800 syringes per minute. The overall equipment effectiveness doubled from 35 per cent to over 70 per cent. The machine can also be configured to package vials, needles and combination packs for other products, if required.

Is TCP a sustainable option?

Ecological, small-volume cartons made from mono-material, which allow for volume reduction, are proving a must. They mean overall savings for many sectors, including logistics, volumes, materials and, in particular, the cold chain. On top of that, of course, they provide sustainable solutions: a hugely topical issue. All of this ties in well with what we are trying to achieve using TCP.

Is it a stand-alone solution, or should it be combined with other methods for best results?

In itself it is a complete solution – that is the good thing about it. Innovative packaging engineering is considered together with the customer and the machinery, providing a better overall solution. In addition, if the product requires blister or other packaging options to be added, this is easily adaptable.

Do you think that TCP and sustainable options are likely to become more widespread over the next few years?


Cost reduction is always going to be a factor. Choosing a mono-material packaging solution ensures sustainable methods, so I can certainly see its potential for widespread usage within the industry.

How do you think the pharma industry will change over the next decade?

People are living longer; illnesses like diabetes are increasing; personalised medicine is moving forward. All of these things will demand a high level of technology in the secondary packaging sector for targeted therapies and long-lasting medication. Being aware of green issues will enable the industry to adapt and stay environmentally safe.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christoph Hammer has held the position of Chief Technical Officer and Deputy Chief Executive Officer at Dividella in Grabs for the past 14 years. He holds a lot of experience in the food and pharmaceutical packaging industry in the fields of engineering and consulting. His expertise covers the capital equipment industry, and through extensive sales activities he has an excellent knowledge of international markets. Christoph was educated as an electrical engineer with additional degrees in Business and Production Technology.
spacer
Christoph Hammer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement